{"id":736930,"date":"2025-03-24T15:26:01","date_gmt":"2025-03-24T15:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=736930"},"modified":"2025-03-24T15:26:01","modified_gmt":"2025-03-24T15:26:01","slug":"cart-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cart-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies_736930.html","title":{"rendered":"CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/03\/1742809306.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/03\/1742809306.jpg\" alt=\"CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, <strong>&ldquo;CAR-T Pipeline Insight 2025&rdquo;<\/strong> report provides comprehensive insights about <strong>180+ companies and 200+ pipeline drugs<\/strong> in CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CAR-T pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in CAR-T Research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">CAR-T Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the CAR-T Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>In March 2025, BeiGene<\/em><\/strong> announced a study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.<\/li>\n<li><strong><em>In March 2025, Celgene<\/em><\/strong> announced a study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).<\/li>\n<li><strong><em>In March 2025, Hoffmann-La Roche<\/em><\/strong> announced a study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).<\/li>\n<li><strong><em>In March 2025, Allogene Therapeutics<\/em><\/strong> announced a study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY&trade; Investigational Use Only (IUO) MRD test, powered by PhasED-Seq&trade;. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.<\/li>\n<li><strong><em>In March 2025, Regeneron Pharmaceuticals<\/em><\/strong> announced a study study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as &#8216;refractory&#8217;) or has returned (also known as &#8216;relapsed&#8217;). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.<\/li>\n<li><strong><em>In March 2025, Genmab<\/em><\/strong> announced a phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma<\/li>\n<li>DelveInsight&rsquo;s CAR-T pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR-T treatment.<\/li>\n<li>The leading CAR-T Companies such as <strong><em>Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research &amp; Development, Beijing Immunochina Medical Science &amp; Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals<\/em><\/strong>, and others.<\/li>\n<li>Promising CAR-T Therapies such as <strong><em>IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide,<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in CAR-T treatments. Download for updates and be a part of the revolution in care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">CAR-T Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CAR-T Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Descartes-08: Cartesian Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>KYV-101: Kyverna Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1\/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA&#8217;s IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I\/II trial for systemic sclerosis.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TX200: Sangamo Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">TX200 is composed of the patient&rsquo;s own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I\/II stage of its clinical trial.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ALLO-605: Allogene Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ALLO-605, a next-generation AlloCAR T&trade; known as a TurboCAR&trade;, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed\/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene&#8217;s proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene&rsquo;s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed\/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I\/II stage of its clinical trial for the treatment of Multiple Myeloma.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ATA3219: Atara Biotherapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin&rsquo;s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>CB-010 : Caribou Biosciences<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r\/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r\/r B-NHL.<\/p>\n<p style=\"text-align: justify;\"><strong> The CAR-T Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of CAR-T with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR-T Treatment.<\/li>\n<li>CAR-T Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>CAR-T Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR-T market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn more about CAR-T Drugs opportunities in our groundbreaking CAR-T Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">CAR-T Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CAR-T Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research &amp; Development, Beijing Immunochina Medical Science &amp; Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>CAR-T Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in CAR-T treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of disease @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">CAR-T Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the CAR-T Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>CAR-T Companies- <strong><em>Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research &amp; Development, Beijing Immunochina Medical Science &amp; Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Atara Biotherapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals<\/em><\/strong>, and others.<\/li>\n<li>CAR-T Therapies- <strong><em>IM23, C-CAR066, AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells, Fludarabine, Cyclophosphamide<\/em><\/strong>, and others.<\/li>\n<li>CAR-T Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>CAR-T Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of CAR-T Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">CAR-T Emerging Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>CAR-T: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>CAR-T&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Descartes-08: Cartesian Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>ATA3219: Atara Biotherapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>CAR-T Key Companies<\/li>\n<li>CAR-T Key Products<\/li>\n<li>CAR-T- Unmet Needs<\/li>\n<li>CAR-T- Market Drivers and Barriers<\/li>\n<li>CAR-T- Future Perspectives and Conclusion<\/li>\n<li>CAR-T Analyst Views<\/li>\n<li>CAR-T Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cart-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cart-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;CAR-T Pipeline Insight 2025&rdquo; report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T pipeline therapeutics &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cart-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies_736930.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-736930","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/736930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=736930"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/736930\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=736930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=736930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=736930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}